The Medicines Company  

(Public, NASDAQ:MDCO)   Watch this stock  
Find more results for MDCO
+0.99 (3.26%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.25 - 32.00
52 week 19.92 - 34.70
Open 30.39
Vol / Avg. 1.63M/1.46M
Mkt cap 2.08B
P/E     -
Div/yield     -
EPS -0.97
Shares 66.23M
Beta 1.16
Inst. own 108%
Oct 20, 2015
Q3 2015 Medicines Co Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 29, 2015
Q2 2015 Medicines Co Earnings Release
Jul 29, 2015
Q2 2015 Medicines Co Earnings Call - Webcast
Jun 23, 2015
The Medicines Company Announces FDA Approval of KENGREALT Corporate Call
Jun 2, 2015
Medicines Co to Discuss Clinical Trial Results of ABP-700 and MDCO-216 Conference Call - Webcast
Jun 1, 2015
Medicines Co at Jefferies Global Healthcare Conference - Webcast
May 28, 2015
Medicines Co Annual Shareholders Meeting
May 14, 2015
Medicines Co at Bank of America Merrill Lynch Health Care Conference - Webcast
May 5, 2015
Q1 2015 Medicines Co Earnings Release
May 5, 2015
Q1 2015 Medicines Co Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -51.44% -4.47%
Operating margin -87.31% -9.95%
EBITD margin - -0.88%
Return on average assets - -1.78%
Return on average equity - -3.55%
Employees 727 -
CDP Score - -


United States - Map
+1-973-2906000 (Phone)
+1-973-6569898 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


The Medicines Company is a global biopharmaceutical company. The Company's marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Company's products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Company's four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.

Officers and directors

Clive A. Meanwell M.D., Ph.D. Chairman of the Board, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Glenn P. Sblendorio President, Chief Financial Officer, Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jeffrey Frazier Executive Vice President, Chief Human Strategy Officer
Age: 52
Bio & Compensation  - Reuters
William B. O'Connor Senior Vice President, Chief Accounting Officer
Age: 56
Bio & Compensation  - Reuters
Stephen M. Rodin J.D. Senior Vice President, General Counsel, Secretary
Age: 39
Bio & Compensation  - Reuters
Elizabeth H.S. Wyatt Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
William W. Crouse Independent Director
Age: 72
Bio & Compensation  - Reuters
Robert J. Hugin Independent Director
Age: 60
Bio & Compensation  - Reuters
John C. Kelly Independent Director
Age: 72
Bio & Compensation  - Reuters
Armin M. Kessler Independent Director
Age: 77
Bio & Compensation  - Reuters